Display Settings:

Format

Send to:

Choose Destination

    Orv Hetil. 2004 Dec 26;145(52):2619-21.

    [Warfarin or acenocoumarol is better in the anticoagulant treatment of chronic atrial fibrillation?]

    [Article in Hungarian]

    Lengyel M; SPORTIF-III Altanulmány Vizsgálói.

    Gottsegen György Országos Kardiológiai Intézet, Budapest.

    A SPORTIF-III substudy. BACKGROUND: Warfarin has been considered to provide more stable anticoagulant effect than acenocoumarol due to its longer half-life. OBJECTIVE: The aim of this SPORTIF-III substudy was to compare acenocoumarol (A) with warfarin (W) in the same group of 74 patients, with chronic atrial fibrillation who started with W and then changed to A. METHODS: We compared prospectively a 3 months period on W with a 3 months period on A. RESULTS: The mean number of INR measurements per patient was 5.7 +/- 1.2 and 5.4 +/- 1.6 resp (NS). The mean percentage of INR-s in the therapeutic range of 2-3 was 49 +/- 22.6% for W and 56 +/- 26.8% for A (p < 0.05), the percentage of subtherapeutic values were not different, the supratherapeutic values however occurred more frequently on W (28 +/- 20%) than on A (19 +/- 19%), p < 0,001. There was a good correlation between A and W doses (r = 0.65, p < 0.001), the mean W dose was 5.03 +/- 1.99 mg, the mean A dose was 2.5 +/- 1.3 mg, the W/A dose ratio was computed to be 2.18 +/- 0.78. CONCLUSIONS: 1. anticoagulation effect stability was superior for A compared to W; 2. W/A dose ratio was 2.18.

    PMID: 15724697 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Patient drug information

    • Warfarin (Coumadin®)

      Warfarin is used to prevent blood clots from forming or growing larger in your blood and blood vessels. It is prescribed for people with certain types of irregular heartbeat, people with prosthetic (replacement or mechan...